Evidence map›Paper›PMID 36048127›Full record

ArticleHuman vaccines & immunotherapeutics2022

Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report.

Guang Zeng, Jie Tang, Shuidong Feng, Liumei Xu, Xiaohui Wang, Zhengrong Yang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Inactivated COVID-19 vaccines, HBV and HIV: Correspondence.Human vaccines & immunotherapeutics · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Guang ZengDepartment of HIV/AIDS Prevention and Control, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.ORCID 0000-0003-4127-5775
Jie TangSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, China.
Shuidong FengSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, China.
Liumei XuNational Clinical Research Centre for Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, China.
Xiaohui WangDepartment of HIV/AIDS Prevention and Control, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
Zhengrong YangDepartment of HIV/AIDS Prevention and Control, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
Shenzhen Center for Disease Control and Prevention · CNUniversity of South China · CNShenzhen Third People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including people living with HIV (PLWH). At present, there are no reports of HIV/hepatitis B virus (HBV) co-infected patients receiving a booster dose of the inactivated COVID-19 vaccine. Here, we describe a patient with HIV/HBV co-infection who did not seroconvert to three doses of the inactivated COVID-19 vaccine.

Indexed as

CoinfectionCOVID-19Hepatitis BHIV InfectionsCD4 Lymphocyte CountCOVID-19 VaccinesHepatitis B VaccinesHepatitis B virusHumansPandemicsVaccines, InactivatedCOVID-19 VaccinesHepatitis B VaccinesVaccines, InactivatedCD4+T cell countHIV/HBV co-infectioninactivated COVID-19 vaccinepeople living with HIVspike receptor binding domain IgG (S-RBD-IgG) antibodyviral load (VL)

Identifiers

PMID36048127
PMCPMC9746420
OpenAlexW4294125937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.